Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NovaBay Pharmaceuticals Inc (NBY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NBY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0.85
1 Year Target Price $0.85
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.57% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.52M USD | Price to earnings Ratio 0.02 | 1Y Target Price 0.85 |
Price to earnings Ratio 0.02 | 1Y Target Price 0.85 | ||
Volume (30-day avg) 1 | Beta 0.41 | 52 Weeks Range 0.44 - 1.01 | Updated Date 08/15/2025 |
52 Weeks Range 0.44 - 1.01 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 24.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 37.43% | Operating Margin (TTM) -55.04% |
Management Effectiveness
Return on Assets (TTM) -44.19% | Return on Equity (TTM) -240.71% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value -3818360 | Price to Sales(TTM) 0.36 |
Enterprise Value -3818360 | Price to Sales(TTM) 0.36 | ||
Enterprise Value to Revenue 0.27 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 5816200 | Shares Floating 4795460 |
Shares Outstanding 5816200 | Shares Floating 4795460 | ||
Percent Insiders 0.02 | Percent Institutions 24.5 |
Upturn AI SWOT
NovaBay Pharmaceuticals Inc
Company Overview
History and Background
NovaBay Pharmaceuticals Inc. was founded in 2000. The company is focused on developing and commercializing anti-infective products for the eye care market.
Core Business Areas
- Eye Care: NovaBay develops and markets products for the eye care market, including Avenova, a prescription antimicrobial eyelid and lash cleanser.
Leadership and Structure
The leadership team includes board members such as Paul Freiman as CEO and Thomas J. Rowe as Chairman. The structure is a typical pharmaceutical company structure.
Top Products and Market Share
Key Offerings
- Avenova: Avenova is an antimicrobial eyelid and lash cleanser used to treat blepharitis and dry eye. Market share data is difficult to pinpoint precisely but it competes with other eyelid cleansers. Competitors include Ocusoft and Systane.
Market Dynamics
Industry Overview
The eye care market is growing, driven by an aging population and increasing prevalence of dry eye and other ocular surface diseases.
Positioning
NovaBay is positioned in the prescription eye care market with a focus on antimicrobial solutions. Its competitive advantage lies in the formulation and efficacy of Avenova.
Total Addressable Market (TAM)
The TAM for dry eye and blepharitis treatments is estimated to be in the billions of dollars. NovaBay holds a small portion of this total market but is trying to grow. Difficult to determine an exact value.
Upturn SWOT Analysis
Strengths
- Proprietary Avenova formulation
- Focus on underserved eye care needs
- Established sales and distribution network
Weaknesses
- Limited product portfolio
- Dependence on a single key product (Avenova)
- Small market capitalization and potential for stock dilution
Opportunities
- Expansion into new markets and geographies
- Development of new products for related eye conditions
- Potential for partnerships and collaborations
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes and approvals
- Patent expiration and generic competition
Competitors and Market Share
Key Competitors
- ALVR
- OCUL
- EYPT
Competitive Landscape
NovaBay is a smaller player in the eye care market, competing with larger, more established companies. Its advantage lies in its unique Avenova formulation, but it faces challenges in terms of marketing and distribution reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of revenue growth followed by declines. Difficult to extract positive growth trends.
Future Projections: Analyst projections are generally cautious, reflecting the company's volatile financial performance. Expect revenue to rise if Avenova sales improve.
Recent Initiatives: Recent initiatives include new marketing campaigns for Avenova and efforts to expand distribution channels.
Summary
NovaBay Pharmaceuticals is a small company focused on the eye care market, primarily with its Avenova product. Its financial performance has been inconsistent, and it faces strong competition from larger players. The company's growth depends on successful marketing and expansion of Avenova, and new products are needed to address risks of low diversification. The key will be to leverage the unique properties of Avenova and increase sales.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Third-Party Financial Data Providers
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NovaBay Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2007-10-26 | President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director Mr. Justin M. Hall Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://novabay.com |
Full time employees 13 | Website https://novabay.com | ||
NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.